چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده | نفر چندم مقاله |
|---|---|
| فرزانه صادقی | اول |
| الهام کمال کاظمی | دوم |
| مهناز صادقی | سوم |
| محمد مصطفی پورسیف | چهارم |
| عفت علیزاده | پنجم |
| عنوان | متن |
|---|---|
| کلمات کلیدی | mRNA vaccine; vaccine constructs; infectious disease; cancer vaccine |
| خلاصه مقاله | Introduction: The mRNA was first discovered in 1961 while studying the protein synthesis mechanism of DNA. In 1978 and 1989, it was revealed that mRNA could be delivered into the cell by liposome or cationic lipid carriers to express proteins. In 1990, the first in vitro transcribed mRNA (IVT mRNA) was directly injected into a mouse skeleton muscle. The emergence of safe and effective mRNA vaccines has opened a new era for vaccine development. Since the mRNA can induce both cellular and humoral immunity while presenting an mRNA encoded antigen, it has been regarded as a powerful vaccine system. Compared with conventional vaccine technologies, the superiority of mRNA vaccines regarding simplicity and adaptability in antigen design, high translation efficiency with direct delivering antigen into the cytoplasm, no risk of insertion mutagenesis, rapid and low-cost production, encourages pharmaceutical industries to expand their application to a diverse array of diseases. Methods: We focused on recently published original articles regarding mRNA vaccines and summarized/dissected the main beneficial outcomes of them. Result and Discussion: There are three types of synthetic mRNA to modulate protein expression on specific purpose, including linear type mRNA, self-amplifying mRNA (SAM) and circular mRNA. Several methods have been developed to synthetic mRNA production containing 4 major steps: (1) specific antigen selection, (2) DNA template synthesis, (3) in vitro mRNA transcription, (4) mRNA purification. Starting with SARS-CoV-2, several mRNA vaccines against infectious diseases such as HIV-I, Zika, rabies and Influenza A are undergoing clinical trials. mRNA vaccines can be used also for cancer immunotherapy which encodes tumor-associated antigens (TAA) or neoantigens. DC-based vaccine (sipuleucel-T) approved by the FDA for the treatment of hormone-refractory prostate cancer. On May 2024 the FDA has approved the new drug application of WGc-043, an Epstein-Barr virus-related mRNA cancer vaccine. This Review provides a detailed overview of mRNA vaccines, including their principles, manufacture, application and future directions in advancing this promising vaccine platform to widespread therapeutic use. |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| 22_653_Farzaneh Sadeghi.jpg | 1403/08/29 | 607192 | دانلود |
| G-1516.pdf | 1403/08/29 | 854428 | دانلود |
| mRNA Vaccine.docx | 1403/05/01 | 16140 | دانلود |
| 91231099.pdf | 1403/05/02 | 4276550 | دانلود |
